IQWiG finds no added benefit for Dendreon's Provenge or Gilead's Zydelig
This article was originally published in Scrip
There is no proven benefit for either Dendreon's prostate cancer treatment Provenge (Sipuleucel-T) or Gilead's Zydelig (idelalisib) for follicular lymphoma or chronic lymphocytic leukaemia, according to IQWiG, Germany's health technology appraisal body.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.